Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir cialis Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.

Palosverdesmedicalgroup.net

Peninsula Research Associates, Inc.
550 Deep Valley Dr., Suite 317
Rolling Hills Est. Ca 90274
Phone 310-265-1623/Fax 310-265-1753
E-Mail: lsher@pratrials.com

Laurence K. Gorlick, M.D.
Office Address
550 Deep Valley Dr. Suite 319
Rolling Hills Est. Ca 90274
Phone 310-544-6858 Fax 310-544-6855
Los Alamitos, Ca 90720
Phone 562-594-9546
Clinical Research Affiliations
Peninsula Research Associates, Inc. (Aug 1999- Present)
550 Deep Valley Dr. Suite 317
Rolling Hills Est. Ca 90274
Phone 310-265-1623 Fax 310-265-1753
Medical Licence
California #A036580
DEA #BG3028633
Medical Education and Training
College:
Kingsborough Community College,
Brooklyn, New York
Graduated 1971, Associates in Arts
Brooklyn College,
Brooklyn, New York
Graduated 1973, Bachelor of Arts in Psychology
Curriculum Vitae Last Updated 12/02/2010 Laurence K. Gorlick, M.D. Curriculum Vitae Page 2 University Autonoma de Guadalagara ECFMG# 266-930-7 Brookdale Medical Center
Brooklyn, New York
Completed in 1978
Internship:
Long Island College Hospital
Brooklyn, New York
Completed 1979
Residency:
Norwalk Hospital, Internal Medicine
Norwalk, Connecticut
Completed 1981

Hospital Affiliations

Torrance Memorial Medical Center 3330 Lomita Blvd. Torrance, Ca 90505 310-325-9110 Little Company of Mary Hospital 4101 Torrance Blvd. Torrance, Ca 90503 Phone 310-540-7676 Curriculum Vitae Last Updated 12/02/2010 Laurence K. Gorlick, M.D.
Curriculum Vitae
Page 3
Awards:
AMA Physician Recognition Award- January 1995 - January 2001
January 1992 - January 1995
March 1989 - January 1992
August 1986 - August 1989
August 1983 - August 1986
August 1980 - August 1983
Medical Organizations:
American Society of Internal Medicine
American Medical Association
Los Angeles County Medical Association
Long Beach Society of Internal Medicine
Elected or Appointed Positions:
Medical Director, ProHealth Diagnostic Services 1995-2000
Chairman- ProHealth Anciliary Services 1995-present
Chairman- Credentials Committee- St. Mary Medical Center
1993-1995
Faculty Appointments:
Associate Professor of Medicine
UCLA St. Mary Medical Center, Long Beach, CA
1985-2006
Clinical Instructor UCLA
Curriculum Vitae Last Updated 12/02/2010 Laurence K. Gorlick, M.D.
Curriculum Vitae
Page 4
Clinical Trial Experience:
 An Open-Label, Multicenter, No-Comparative Study of Oral Gatifloxacin in the Treatment of Community-Acquired Respiratory Tract Infections  The Micardis Community Acess Trial (MICCAT) for treatment of  Protocol AI-464-022 BMS- phase III, Acute Bacterial  Protocol AI-464-024 BMS- phase III, Acute Maxillary Sinusitis  Protocol AI-646-029 BMS- phase III, Community Acquired  Protocol CV-137-120 BMS- phase III, Comparative Trial of Two Antihypertensive Medications in Patients With Hypertension  Eli Lilly Protocol B4Z-US-LYBV- Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Strattera in Adults with Attention-Deficit/Hyperactivity Disorder  Eli Lilly Protocol B4Z-US-LYCW: A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adult with Attention-Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning  Merck Protocol 010-02- Phase III, Multicenter, Double-Blind, Randomized, Placebo- and Active-Control Dose-Range Finding Study of L-000224715 in Patients with Type II Diabetes Mellitus who have Inadequate Glycemic Control  Merck Protocol 034-00- Phase III, a Multicenter, Double-Blind, Randomized, Active Controlled, Parallel Group Study to Evaluate the Lipid-Altering Efficacy of MK0767 in Patients with Type II Diabetes and Dyslipidemia Curriculum Vitae Last Updated 12/02/2010 Laurence K. Gorlick, M.D. Curriculum Vitae Page 5  BMS Protocol CV168-021- Phase III, randomized, double-blind, placebo controlled, multicenter trial to evaluate safety and efficacy of BMS 298585 in combination with Glyburide in subjects with Type II Diabetes who have inadequate glycemic control on Sulfonylurea therapy alone  BMS Protocol CV168-022- Phase III, randomized, double-blind, placebo controlled, multicenter trial to evaluate safety and efficacy of BMS 298585 study drug in combination with Metformin in subjects with Type II Diabetes who have inadequate glycemic control on Metformin alone  BMS Protocol CV168-025- Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Evaluate Safety and Efficacy of BMS 298585 Study Drug in Combination with Metformin in subjects with Type II Diabetes who have inadequate Metformin Control on Metformin alone  BMS Protocol CV168-006- Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Evaluate Safety and Efficacy of BMS 298585 Study Drug Compared to Piaglitazone in Type II Diabetics not Currently on Medication Treatment  Pfizer Protocol A3841001- Phase III, Randomized, Double-Blind, Placebo-Controlled and Open-Label Evaluation of the Safety and Efficacy of dual Therapy with Atorvastatin Plus Amlodipine When Compared to Either Therapy Alone in the Treatment of Patients with simultaneous Hyperlipidemia and Hypertension  BMS Protocol CV137-120 -Phase III, Randomized, Placebo Controlled Trial of Omapatralide and Enalapril  Bristol Myers Squibb, Protocol CV131-176: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension  Bristol Myers Squibb, Protocol CV131-185: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Moderate Hypertension Curriculum Vitae Last Updated 12/02/2010

Source: http://www.palosverdesmedicalgroup.net/docs/Gorlick%20CV.pdf

5989_9241en.qxd

Development and validation of an HPLC method to analyze ibuprofen and impurities according to the European Pharmacopoeia Abstract This Application Note describes the development of a fast, accurate,and reproducible method to analyze ibuprofen and related impuritiesaccording to European Pharmacopoeia (EP) regulations1, using anAgilent 1120 Compact LC. The experiments described in thisAp

310290 lyrica folder

Lyrica® Hoe zien de Lyrica® capsules eruit en hoeveel zitten er in een Uw arts heeft u het geneesmiddel Lyrica® (pregabaline) voorgeschreven en heeft verpakking u ook uitgelegd waarom u dit middel gaat gebruiken. - 75 mg capsule: wit-oranje harde gelatine capsule met de opdruk “Pfizer” op het Deze folder is samengesteld om u nog eens schriftelijk te informeren over de eigensc

Copyright © 2010-2014 Internet pdf articles